Standard Chemical & Pharmaceutical Co., Ltd. (1720.TW) has a MoatMap StockRank of 99/100 based on Quality (72/100), Value (73/100), and Momentum (54/100) factor scores. The current signal is STRONG BUY. Standard Chemical & Pharmaceutical, a Taiwanese healthcare company, aligns strongly with the 'Healthcare Technology & Resilience' theme. The market often undervalues healthcare's defensive growth attributes and the transformative impact of technology on efficiency and patient outcomes, creating an unpriced opportunity. As a pharmaceutical entity in Taiwan – a hub for advanced technology – it likely benefits from non-discretionary demand, robust R&D, and intellectual property, implying a durable economic moat and pricing power. This provides asymmetric upside from resilient earnings in an uncertain macro environment, further supported by potential technology integration fueled by 'Asia's AI-Driven Growth'.
| Price | $1.95 |
| Market Cap | $353M |
| P/E (TTM) | 11.81 |
| P/E (Forward) | 12.29 |
| Price/Book | 1.80 |
| Return on Equity | 14.5% |
| Return on Invested Capital | 15.8% |
| Debt/Equity | 10.10 |
| Gross Margin | 41.6% |
| Operating Margin | 20.8% |
| Revenue Growth | 0.7% |
| Dividend Yield | 4.5% |
| Free Cash Flow | $805K |
Standard Chemical & Pharmaceutical Co., Ltd. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (Taiwan).